The trajectory of companies tied to Sildenafil's history presents a intricate investment picture . While the initial surge generated substantial returns , generic competition have significantly eroded sales . Investing in associated pharmaceutical firms now requires a discerning assessment of intellectual property protection , evolving medical shif